Dec 23, 2025 · Orserdu (chemical name: elacestrant) is a type of medicine called a selective estrogen receptor downregulator (SERD). It’s used to treat estrogen receptor-positive, HER2-negative breast …

Nov 7, 2025 · INDICATION ORSERDU (elacestrant) is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 …

Orserdu (elacestrant) is a targeted hormonal therapy for breast cancer. Unlike chemotherapy, which can harm both healthy and cancer cells, targeted therapy aims at specific proteins in the cancer ...

Apr 23, 2024 · Orserdu works by blocking the effect of estrogen on the hormone receptor-positive breast cancer cells, changing the shape of estrogen receptors so they don’t work properly, and decreasing …

Mar 23, 2025 · Discover Elacestrant (Orserdu) for ER+/HER2- breast cancer: uses, side effects, dosage, expectations, and key facts patients need to know.

Orserdu is an estrogen receptor antagonist used to treat postmenopausal women or adult men with ERpositive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Orserdu may …

Oct 13, 2025 · The oral SERDs elacestrant (Orserdu) and imlunestrant (Inluriyo) are FDA-approved for use in metastatic breast cancer treatment. They can each be used to treat hormone receptor …

Elacestrant (Orserdu®) has info patients should know about. Read, listen, and watch videos about side effects from Elacestrant (Orserdu®) for Breast Cancer – metastatic.

Elacestrant (Orserdu) is a hormone (endocrine) therapy. Abbreviated as LABC and sometimes called regional recurrence. Breast cancer that has come back and has spread to the chest wall or skin of …

5 days ago · The Norwegian Directorate of Medical Products (DMP) assessed Menarini Stemline’s Orserdu (elacestrant) as monotherapy for the treatment of postmenopausal women, and men, with …